Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Home Page: www.abbvie.com
1 North Waukegan Road
North Chicago,
IL
60064-6400
United States
Phone:
847 932 7900
Officers
Name | Title |
---|---|
Mr. Richard A. Gonzalez | Chairman & CEO |
Mr. Robert A. Michael | Vice Chairman & Pres |
Ms. Laura J. Schumacher | Vice Chairman of External Affairs & Chief Legal Officer |
Mr. Jeffrey Ryan Stewart | Exec. VP & Chief Commercial Officer |
Mr. Scott T. Reents | Exec. VP & CFO |
Dr. Azita Saleki-Gerhardt Ph.D. | Exec. VP of Operations |
Dr. Thomas J. Hudson | Sr. VP of R&D and Chief Scientific Officer |
Ms. Elizabeth Shea | VP of Investor Relations |
Mr. Perry C. Siatis | Exec. VP, Gen. Counsel & Sec. |
Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer |
Exchange: F
Country: DE
Currency: Euro (€)
Forward PE: | 14.2653 |
---|---|
Trailing PE: | 20.5092 |
Price-to-Book MRQ: | 18.0664 |
Price-to-Sales TTM: | 4.7246 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 50000 |